• Sep.26 (THU)
  • Sep.27 (FRI)

Sep.26(THU)

ASCO/KSMO Joint Symposium 1 (JS01)

Oncology innovations in cancer care - Translating new discoveries into treatment for patients with cancer
Date & Time Sep. 26 (Thu), 08:40-10:20 Venue Room A
Presentation
Detail
  1. 1.Strategies to therapeutically target dormant cells and reactivated Minimal Residual Disease (MRD): Challenges and opportunities
    Angela DeMichele (University of Pennsylvania, USA)
  2. 2.Recent advances in GI cancers- New targets, new treatments
    Rachna Shroff (University of Arizona Cancer Center, USA)
  3. 3.DDR inhibitors in clinical trials: dissecting responders/nonresponders for optimal treatment
    Hyo Song Kim (Yonsei University College of Medicine, Korea)
  4. 4.Platform trials with biomarkers in solid tumors: Opportunities and challenges
    Se-Hoon Lee (Samsung Medical Center, Korea)

Scientific Symposium 1 (SS01)

Navigating current and emerging therapies for breast cancer
Date & Time Sep. 26 (Thu), 08:50-10:20 Venue Room B
Chair(s)
  • Sung-Bae Kim (Asan Medical Center, Korea)
  • Giuseppe Curigliano (European Institute of Oncology, IRCCS and Università degli Studi di Milano, Italy)
Presentation
Detail
  1. 1.Breast cancer in pre-menopausal women: challenges, treatment options, and future perspectives
    Yeon Hee Park (Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea)
  2. 2.Discovery and development of Capivasertib: A journey in targeted cancer therapy
    Paul Workman (Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK)
  3. 3.Overcoming drug resistance in Breast cancer
    Giuseppe Curigliano (European Institute of Oncology, IRCCS and Università degli Studi di Milano, Italy)

Education Session 1 (ES01)

ABCs of toxicities management for medical oncologist: Our OLD and NEW foes KOREAN
Date & Time Sep. 26 (Thu), 08:50-10:20 Venue Room C
Chair(s)
  • Sook Ryun Park (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.Practical consideration of fertility preservation during chemotherapy : Based on latest update
    Sung Hoon Kim (Asan Medical Center, Korea)
  2. 2.Optimal management of chemotherapy-induced peripheral neuropathy : In neurologists perspectives
    Su-Hyun Kim (National Cancer Center, Korea)
  3. 3.Getting famila with toxicities of ADCs: Focusing on currently available ADC drugs
    Hee-Jun Kim (Chung-Ang University College of Medicine, Korea)
  4. 4.Tips for monitoring, management and prediction of irAEs: In oncoligist's perspectives
    Se Hyun Kim (Seoul National University Bundang Hospital, Korea)

Satellite Symposium 1 (SL01)

First-line treatment in metastatic colorectal cancer
Date & Time Sep. 26 (Thu), 08:50-09:30 Venue Room E
Chair(s)
  • Jong Gwang Kim (Kyungpook National University Hospital, Korea)
Presentation
Detail
  1. The necessity of FOLFOXIRI as first-line treatment in patients with metastatic colorectal cancer
    TBD

Satellite Symposium 2 (SL02)

New treatment options for NSCLC patients with METex14 skipping alterations
Date & Time Sep. 26 (Thu), 09:40-10:20 Venue Room E
Presentation
Detail
  1. New treatment options for NSCLC patients with METex14 skipping alterations
    Sun Min Lim (Yonsei Cancer Center, Korea)

Plenary Lecture 1 (PL01)

Lessons learned after 50+years of cancer drug development
Date & Time Sep. 26 (Thu), 10:50-11:30 Venue Room A
Presentation
Detail
  1. Lessons learned after 50+years of cancer drug development
    Daniel D. Von Hoff (Translational Genomics Research Institute, USA)

Luncheon Symposium 1 (LS01)

Recent treatment update in TNBC
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room B
Presentation
Detail
  1. The Role of Pembrolizumab: Redefining treatment for early triple-negative breast cancer
    Jieun Lee (College of Medicine, The Catholic University of Korea, Korea)

Luncheon Symposium 2 (LS02)

EGFRm+ NSCLC (Osimertinib)
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room C
Presentation
Detail
  1. Osimertinib, elevate the standard of care for EGFRm+ NSCLC
    Jeonghwan Youk (Seoul National University Hospital, Korea)

Luncheon Symposium 3 (LS03)

Push the paradigm in mBC: From guidelines to clinical practice of HER2-low
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room D
Presentation
Detail
  1. Push the paradigm in mBC: From guidelines to clinical practice of HER2-low
    Giuseppe Curigliano (European Institute of Oncology, IRCCS and Università degli Studi di Milano, Italy)

Luncheon Symposium 4 (LS04)

Redefining 2L CCA landscape with the arrival of Ivosidenib
Date & Time Sep. 26 (Thu), 11:40-12:20 Venue Room E
Presentation
Detail
  1. Roles of Liposomal irinotecan in metastatic pancreatic cancer redefining 2L CCA landscape with the arrival of Ivosidenib
    TBD

Satellite Symposium 3 (SL03)

Pancreatic cancer: State-of-the-Art Neo/Adjuvant treatment in pancreatic cancer_Guidance for oncologist
Date & Time Sep. 26 (Thu), 12:30-13:10 Venue Room E
Presentation
Detail
  1. Pancreatic cancer: State-of-the-Art Neo/Adjuvant treatment in pancreatic cancer_Guidance for oncologist
    TBD

Scientific Symposium 2 (SS02)

Unlocking new immune checkpoint targets: Beyond PD-1/PD-L1 and CTLA4
Date & Time Sep. 26 (Thu), 12:30-14:00 Venue Room A
Chair(s)
  • Linghua Wang (MD Anderson Cancer Center, USA)
Presentation
Detail
  1. 1.LAG-3 as the third checkpoint inhibitor
    Diwakar Davar (University of Pittsburgh, USA)
  2. 2.Targeting macrophage tetraspans to enhance immune checkpoint blockade
    Chan Kim (CHA Bundang Medical Center, Korea)
  3. 3.B-cell-specific checkpoint molecules
    Sarah Zaghouani (Harvard University, USA)
  4. 4.Biomarkers for novel checkpoint inhibitors
    Yun-Gyoo Lee (Kangbuk Samsung Hospital, Korea)

KCSG/KSMO Joint Symposium 2 (JS02)

Breakthrough of drug development in rare cancers
Date & Time Sep. 26 (Thu), 12:30-14:00 Venue Room B
Chair(s)
  • Peter J O'Dwyer (University of Pennsylvania, USA)
Presentation
Detail
  1. 1.Challenges of drug development in rare cancers
    Eun Joo Kang (Korea University Guro Hospital, Korea)
  2. 2.NCI-MATCH: Lessons for precision oncology
    Peter J O'Dwyer (University of Pennsylvania, USA)
  3. 3.Leverage of tissue agnostic drug development in rare cancers
    Bhumsuk Keam (Seoul National University Hospital, Korea)
  4. 4.Project Pragmatica: Application in rare cancers
    Konstantin Dragnev (Dartmouth Cancer Center, USA)

Education Session 2 (ES02)

Early integration of palliative care KOREAN
Date & Time Sep. 26 (Thu), 12:30-14:00 Venue Room C
Chair(s)
  • Seong-Hoon Shin (Kosin University Gospel Hospital, Korea)
Presentation
Detail
  1. 1.Timely integration of palliative care to improve patient outcomes
    Yu Jung Kim (Seoul National University Bundang Hospital, Korea)
  2. 2.Evidence of early integration of palliative care and progress in the era of Korean ‘Act on Life-Sustaining Treatment Determination’
    Shin Hye Yoo (Seoul National University Hospital, Korea)
  3. 3.Practice for early integration of pallaitive care: Psychological impact of prognostic disclosure and psychiatrist's tips
    Seockhoon Chung (Asan Medical Center, Korea)
  4. 4.Practice for early integration of palliative care: Remote symptom monitoring using digital health
    Su-Jin Koh (Ulsan University Hospital, Korea)

Satellite Symposium 4 (SL04)

Recent treatment update in Biliary Tract Cancer
Date & Time Sep. 26 (Thu), 13:20-14:00 Venue Room E
Chair(s)
  • Myung Ah Lee (The Catholic University of Korea Seoul St. Mary's Hospital, Korea)
Presentation
Detail
  1. Leveraging the power of immunotherapy: Pembrolizumab's breakthrough in biliary tract cancer treatment
    TBD

Asia Young Oncologist Forum (AOF)

Asia-Pacific research networking platform for young oncologists: It’s time to collaborate
Date & Time Sep. 26 (Thu), 13:40-15:40 Venue Room D
Presentation
Detail
  1. 1.The Future of oncology in the Asia Pacific: Challenges and Opportunities
    Changhoon Yoo (Asan Medical Center, Korea)
  2. 2.Cross-Border clinical research collaborations: Success stories and lessons learned
    Aaron Tan(National Cancer Center Singapore, Singapore)
  3. 3.Overcoming clinical research barriers in developing countries
    Tawasapon Thambamroong (Phramongkutklao Hospital and College of Medicine,Thailand)
  4. 4.Ethical, Cultural, and Regulatory Considerations in multinational clinical research among Asia Pacific Countries
    Akihiro Ohba (National Cancer Center, Japan)
  5. 5.Leveraging technology to build capability for multinational research among Asia Pacific Countries
    Young Saing Kim (Gachon University Gil Medical Center, Korea)
  6. 6.Addressing disparities in cancer research
    Omali Pitiyarachchi (UNSW Sydney, Australia)
  7. 7.Panel Discussion
    Rogelio Velasco Jr. (Lung Center of the Philippines, Philippines)
    Vivek Agarwala (Narayana Superspeciality Hospital & Cancer Institute, India)
    Lim Yueh Ni (Sarawak General Hospital, Malaysia)

Satellite Symposium 5 (SL05)

Real-practice of Zolbetuximab treatment in CLDN18.2-positive gastric cancer
Date & Time Sep. 26 (Thu), 14:10-14:50 Venue Room E
Presentation
Detail
  1. Real-practice of Zolbetuximab treatment in CLDN18.2-positive gastric cancer
    Hirokazu Shoji (National Cancer Center Hospital, Japan)

ESMO/KSMO Joint Symposium 3 (JS03)

Emerging issues in the treatment of colon and rectal cancers
Date & Time Sep. 26 (Thu), 14:10-15:40 Venue Room A
Presentation
Detail
  1. 1.Optimal treatment and future developments for MSI-high solid cancer
    Minsuk Kwon (Samsung Medical Center, Korea)
  2. 2.Optimal treatment and future development for localized MSI-High colorectal cancer.
    Myriam Chalabi (Netherlands Cancer Institute, Netherlands)
  3. 3.Current developments on immunotherapy for MSS advanced colorectal cancer.
    Sun Young Kim (Asan Medical Center, Korea)
  4. 4.Optimal treatment for locally advanced rectal cancer.
    Andrés Cervantes (University of Valencia, Spain)

Scientific Symposium 3 (SS03)

Oncology drug development: Translating biomarkers into breakthroughs
Date & Time Sep. 26 (Thu), 14:10-15:40 Venue Room B
Chair(s)
  • Byungjin Hwang (Yonsei University College of Medicine, Korea)
  • Paul Workman (Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK)
Presentation
Detail
  1. 1.Development of drugs targeting HMGB1 to selectively modulate the tumor microenvironment
    Seung Bum Park (Seoul National University, Korea)
  2. 2.Discovery and development of NXP800, a first-in-class activator of GCN2 and the Integrated Stress Response for treatment of ARID1A mutant ovarian cancer
    Paul Workman (Centre for Cancer Drug Discovery, The Institute of Cancer Research, London, UK)
  3. 3.Anti-cancer RNA editing therapy based on telomerase reverse transcriptase (TERT) mRNA-splicing ribozyme
    Seong-Wook Lee (Dankook University / Rznomics Inc., Korea)

Scientific Symposium 4 (SS04)

The forthcoming future of genitourinary cancers
Date & Time Sep. 26 (Thu), 14:10-15:40 Venue Room C
Chair(s)
  • Jae Lyun Lee (Asan Medical Center, University of Ulsan College of Medicine, Korea)
Presentation
Detail
  1. 1.Radioligand therapy in prostate cancer
    Karim Fizazi (University of Paris-Saclay, France)
  2. 2.Changing landscape of systemic treatment in advanced urothelial carcinoma
    Se Hoon Park (Samsung Medical Center, Korea)
  3. 3.Treatment strategies for advanced non-clear cell renal cell carcinomas
    Pavlos Msaouel (MD Anderson Cancer Center, USA)
  4. 4.Adjuvant immunotherapy in GU cancers
    Ji Hyun Park (Konkuk University Medical Center, Korea)

Satellite Symposium 6 (SL06)

Patient centricity with PHESGO: Achieving a win-win strategy
Date & Time Sep. 26 (Thu), 15:00-15:40 Venue Room E
Chair(s)
  • Kyong Hwa Park (Korea University Anam Hospital, Korea)
Presentation
Detail
  1. Patient centricity with PHESGO: Achieving a win-win strategy
    Matteo Lambertini (University of Genova, Italy)

Plenary Lecture 2 (PL02)

Rapidly expanding treatment options in lung cancer
Date & Time Sep. 26 (Thu), 15:50-16:30 Venue Room A
Presentation
Detail
  1. Rapidly expanding treatment options in lung cancer
    Sanjay Popat (The Royal Marsden, UK)

Satellite Symposium 7 (SL07)

Date & Time Sep. 26 (Thu), 16:30-17:10 Venue Room E
Presentation
Detail
  1. TBD
    TBD

KSR/KSMO Joint Symposium 4 (JS04)

AI application on oncology imaging
Date & Time Sep. 26 (Thu), 16:30-17:30 Venue Room A
Presentation
Detail
  1. 1.TBD
    Hyungjin Kim (Seoul National University Hospital, Korea)
  2. 2.AI for breast imaging: Current status and future perspectives
    Jung Hyun Yoon (Severance Hospital, Yonsei University, Korea)
  3. 3.Radiomics: Predicting immunotherapy outcomes through advanced imaging features
    Young Kwang Chae (Northwestern University, USA)

Education Session 3 (ES03)

Technologies revolutionizing cancer treatment and care KOREAN
Date & Time Sep. 26 (Thu), 16:30-17:30 Venue Room B
Chair(s)
  • Young-Woong Won (Hanyang University Guri Hospital, Korea)
  • Kyueng-Whan Min (Uijeongbu Eulji Medical Center, Eulji University, Korea)
Presentation
Detail
  1. 1.Artificial intelligence in cancer diagnosis
    Soo Jeong Nam (Asan Medical Center, Korea)
  2. 2.Robotic surgery for colorectal cancer
    Seung Yoon Yang (Severance Hospital, Korea)
  3. 3.Digital therapeutics in cancer patient care
    Junghee Yoon (Samsung Medical Center, Korea)

MDCD(MDCD)

Optimization of treatment for BRPC/LAPC KOREAN
Date & Time Sep. 26 (Thu), 16:30-17:30 Venue Room C
Chair(s)
  • Hye Jin Choi (Severance Hospital, Korea)
Presentation
Detail
  1. 1.TBD
    Jin Won Kim (Seoul National University Bundang Hospital, Korea)
  2. 2.TBD
    In Woong Han (Samsung Medical Center, Korea)
  3. 3.TBD-Radiation Oncology
    Eui Kyu Chie (Seoul National University, Korea)

Sep.27(FRI)

Satellite Symposium 8 (SL08)

What is the roles of FTD/TPI for the treatment of CRC/GC patients? (Draft)
Date & Time Sep. 27 (Fri), 08:40-09:20 Venue Room E
Chair(s)
  • Soohyeon Lee (Korea University Anam Hospital, Korea)
Presentation
Detail
  1. TBD
    TBD

Satellite Symposium 9 (SL09)

ADC in the treatment of metastatic triple-negative breast cancer (TBD)
Date & Time Sep. 27 (Fri), 09:20-10:00 Venue Room E
Chair(s)
  • Sung-Bae Kim (Asan Medical Center, Korea)
Presentation
Detail
  1. Optimal management of mTNBC: Where are we now (TBD)
    Ji Yeon Kim (Samsung Medical Center, Korea)

JSMO/KSMO Joint Symposium 5 (JS05)

Moving the immune checkpoint inhibitors into the partner of surgery
Date & Time Sep. 27 (Fri), 09:20-10:50 Venue Room A
Chair(s)
  • Seung Tai Kim (Samsung Medical Center, Korea)
Presentation
Detail
  1. 1.Perioperative therapy (adjuvant or neoadjuvant) including immune checkpoint inhibitor in Gastric cancer
    Joon Young Hur (Hanyang University Guri Hospital, Korea)
  2. 2.Perioperative therapy (adjuvant or neoadjuvant) including immune checkpoint inhibitor in Colon cancer
    Jeong Eun Kim (Asan Medical Center, Korea)
  3. 3.Perioperative therapy (adjuvant or neoadjuvant) including immune checkpoint inhibitor in Lung cancer
    Hidehito Horinouchi (National Cancer Center Hospital Department of Thoracic Oncology, Japan)
  4. 4.Perioperative therapy (adjuvant or neoadjuvant) including immune checkpoint inhibitor in Esophageal squoamous cell cancer
    Ken Kato (National Cancer Center Hospital, Japan)

KSP/KSMO Joint Symposium 6 (JS06)

Application of digital pathology in precision medicine: Current and future
Date & Time Sep. 27 (Fri), 09:20-10:50 Venue Room B
Chair
  • Cheol Lee (Seoul National University College of Medicine, Korea)
Presentation
Detail
  1. 1.TBD
    Yoon-La Choi (Samsung Medical Center, Korea)
  2. 2.Digital and computational pathology: Tools for patient diagnosis and prognostication
    Matthew Hanna (University of Pittsburgh Medical Center,USA)
  3. 3.Deep learning-based whole slide image segmentation for efficient, objective, and reproducible assistance in pathology
    David Joon Ho (National Cancer Center Korea, Korea)
  4. 4.TBD
    Anil Parwani (The Ohio State University, USA)

Scientific Symposium 5 (SS05)

Emerging immunologic weapons beyond PD1, CTLA4, TIGIT, and LAG3 in lung cancer
Date & Time Sep. 27 (Fri), 09:20-10:50 Venue Room C
Chair(s)
  • Dae Ho Lee (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.Unsolved immunotherapy targets beyond PD-1, CTLA-4, TIGIT, and LAG3 in advanced NSCLC
    Tae Min Kim (Seoul National University Hospital, Korea)
  2. 2.Novel class of chemo-immunotherapeutics in lung cancer_immunotherapy related ADC, CAR-T, CAR-NK
    TBD
  3. 3.Targeting tumor microenvironment other than ICI in lung cancer
    Hye Ryun Kim (Yonsei Cancer Center, Korea)
  4. 4.Emerging role of therapeutic personalized vaccines in melanoma and other malignancies
    Patrick Ott (Dana-Farber Cancer Institute, USA)

Satellite Symposium 10 (SL10)

Current Insights on Lutetium-177-PSMA-617 Radioligand Therapy for Metastatic Castration-Resistant Prostate Cancer (TBD)
Date & Time Sep. 27 (Fri), 10:10-10:50 Venue Room E
Presentation
Detail
  1. TBD
    TBD

Plenary Lecture 3 (PL03)

Cancer as a complex system: Tumor-Stroma-Immune interactions
Date & Time Sep. 27 (Fri), 11:00-11:40 Venue Room A
Presentation
Detail
  1. Cancer as a complex system: Tumor-Stroma-Immune interactions
    Linghua Wang (MD Anderson Cancer Center, USA)

Luncheon Symposium 5 (LS05)

A new horizon in small cell lung cancer treatment: The promise of Lurbinectedin
Date & Time Sep. 27 (Fri), 11:50-12:30 Venue Room B
Presentation
Detail
  1. A new horizon in small cell lung cancer treatment: The promise of Lurbinectedin
    TBD

Luncheon Symposium 6 (LS06)

Ribociclib and its role in breast cancer
Date & Time Sep. 27 (Fri), 11:50-12:30 Venue Room C
Presentation
Detail
  1. TBD
    Jee Hyun Kim (Seoul National University, Seoul National University Bundang Hospital, Korea)

Luncheon Symposium 7 (LS07)

Lazertinib: The dawn of a new era in EGFR-mutant NSCLC 1L treatment
Date & Time Sep. 27 (Fri), 11:50-12:30 Venue Room D
Chair(s)
  • Myung-Ju Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. Lazertinib: The dawn of a new era in EGFR-mutant NSCLC 1L treatment
    Beung-Chul Ahn (National Cancer Center, Korea)

Satellite Symposium 11 (SL11)

Journey for HR+/HER2- breast cancer patients with Abemaciclib as standard treatment : Final OS results of Monarch 3 and landmark 5-year data of Monarch E
Date & Time Sep. 27 (Fri), 12:40-13:20 Venue Room E
Chair(s)
  • Joo Hyuk Sohn (Severance Hospital, Korea)
Presentation
Detail
  1. Journey for HR+/HER2- breast cancer patients with Abemaciclib as standard treatment : Final OS results of Monarch 3 and landmark 5-year data of Monarch E
    Kyung-Hun Lee (Seoul National University Hospital, Korea)

ASCO/KSMO Joint Symposium 7 (JS07)

Optimal palliative care for cancer patients
Date & Time Sep. 27 (Fri), 12:40-14:10 Venue Room A
Presentation
Detail
  1. 1.TBD
    Lynn M. Schuchter (American Society of Clinical Oncology, USA)
  2. 2.Palliative Care Integration to Improve The Patient Experience of Cancer Care
    Thomas W. LeBlanc (Duke University School of Medicine and the Duke Cancer Institute, USA)
  3. 3.Insights from healthcare big data for sustainable, long-term cancer control
    Jung Yong Hong (Samsung Medical Center, Korea)
  4. 4.Bridging the gap: Ensuring continuity of care for cancer patients beyond hospital walls
    Jung Hun Kang (Gyeongsand National University, Korea)

Scientific Symposium 6 (SS06)

Novel therapeutic approaches for GI cancers
Date & Time Sep. 27 (Fri), 12:40-14:10 Venue Room B
Presentation
Detail
  1. 1.KRAS inhibitors for GI cancers
    David S. Hong (The University of Texas MD Anderson Cancer Center, USA)
  2. 2.Anti-HER2 treatment for GI cancers
    Choong-kun Lee (Yonsei Cancer Center, Korea)
  3. 3.Is there druggable target beyond anti-VEGF for advanced HCC?
    Stephen L. Chan (CUHK, Hong Kong)
  4. 4.Challenges and advances of immunotherapeutic approaches in pancreatic cancer
    Eileen M. O'Reilly (Memorial Sloan Kettering Cancer Center (MSK), USA)

KSSO/KSMO Joint Symposium 8 (JS08)

Conversion surgery and optimal timing of systemic therapy for GI cancer
Date & Time Sep. 27 (Fri), 12:40-14:10 Venue Room C
Chair(s)
  • Hong Jae Chon (Cha Bundang Medical Center, Korea)
  • Dong Jin Park (University of Ulsan College of Medicine, Korea)
Presentation
Detail
  1. 1.Conversion surgery for advanced HCC
    Junichi Shindoh (Toranomon Hospital, Japan)
  2. 2.Optimal time to start systemic treatment for HCC
    David Tai (National Cancer Centre , Singapore)
  3. 3.How to determine the extent and timing of surgical resection in conversion surgery for advanced gastric cancer?
    Yoo Min Kim (Yonsei University College of Medicine, Korea)
  4. 4.Combined intraperitoneal and systemic chemotherapy for advanced gastric cancer
    So Hyun Kang (Seoul National University Bundang Hospital, Korea)

Scientific Symposium 7 (SS07)

Artificial intelligence-driven optimization drug development process: From target discovery to phase I trial
Date & Time Sep. 27 (Fri), 12:40-14:10 Venue Room D
Chair(s)
  • Joo Sang Lee (School of Medicine, Sungkyunkwan University, Korea)
  • Jimmy Yen-Chu Lin (Insilico Medicine Taiwan, Taiwan)
Presentation
Detail
  1. 1.AI-driven CDK inhibitor response prediction and Homologous Recombination Deficiency prediction in patient samples
    Whijae Roh (Pfizer Oncology (San Diego), USA)
  2. 2.AI-driven novel target discovery bridged by synthetic lethality
    Joo Sang Lee (School of Medicine, Sungkyunkwan University, Korea)
  3. 3.A comprehensive AI-driven analysis of large-scale omic datasets reveals novel dual-purpose targets for the treatment of cancer and aging
    Jimmy Yen-Chu Lin (Insilico Medicine Taiwan, Taiwan)
  4. 4.Transcriptome based AI model to accelerate oncology drug development
    Yi Rang Kim (CEO, Oncocross Co., Ltd., Korea)

Satellite Symposium 12 (SL12)

A new treatment paradigm in advanced urothelial cancer
Date & Time Sep. 27 (Fri), 13:30-14:10 Venue Room E
Presentation
Detail
  1. TBD
    Inkeun Park (Asan Medical Center, Korea)

Plenary Lecture 4 (PL04)

Hepatocellular carcinoma: What is the big picture? and are we seeing it?
Date & Time Sep. 27 (Fri), 14:20-15:00 treatment Room A
Presentation
Detail
  1. Hepatocellular carcinoma: What is the big picture? and are we seeing it?
    Ghassan K. Abou-Alfa (Memorial Sloan Kettering Cancer Center, USA)

Satellite Symposium 13 (SL13)

Immuno-therapy OPDIVO gastric cancer session
Date & Time Sep. 27 (Fri), 15:10-15:50 Venue Room E
Chair(s)
  • Minkyu Jung (Yonsei Cancer Center, Korea)
Presentation
Detail
  1. 1.TBD
    Hyung-Don Kim (Asan Medical Center, Korea)
  2. 2.TBD
    TBD

ESMO/KSMO Joint Symposium 9 (JS09)

New horizon in GI cancer
Date & Time Sep. 27 (Fri), 15:10-16:40 Venue Room A
Presentation
Detail
  1. 1.TBD
    TBD
  2. 2.GI oncology
    Julien Taieb (Université Paris Descartes, France)
  3. 3.Minimal residual disease testing using ctDNA in colorectal cancer
    Sae-Won Han (Seoul National University Hospital, Korea)
  4. 4.Recent updates in clinical treatment for MMR/MSI-H gastrointestinal cancer
    Hyung-Don Kim (Asan Medical Center, Korea)

Scientific Symposium 8 (SS08)

Emerging ADC treatment across cancer types
Date & Time Sep. 27 (Fri), 15:10-16:40 Venue Room B
Chair(s)
  • Kyung Hae Jung (Asan Medical Center, Korea)
Presentation
Detail
  1. 1.Recent updates for ADC treatment in Gynecologic cancers
    Yong Wha Moon (Cha Bundang Medical Center, Korea)
  2. 2.Tissue-agnostic use of T-Dxd for HER2-expressing solid tumors
    Do-Youn Oh (Seoul National University Hospital, Korea)
  3. 3.Optimizing the safety of novel antibody-drug conjugates (ADCs)
    Toshio Shimizu (Wakayama Medical University, Japan)
  4. 4.New CLAUDIN targeting ADCs for cancer treatment
    Gottfried Konecny (UCLA, USA)

KOSRO/KSMO Joint Symposium 10 (JS10)

Integration of systemic therapy and radiotherapy
Date & Time Sep. 27 (Fri), 15:10-16:40 Venue Room C
Chair
  • Icro Meattini (University of Florence, Italy)
Presentation
Detail
  1. 1.Concurrent treatment of RT in breast cancer - Focusing on ADC and CDK4/6 inhibitors
    Icro Meatinni (University of Florence, Italy)
  2. 2.Recent advances in combined treatment including RT for HCC
    Rodney Cheng-En Hsieh (Chang Gung Memorial Hospital, Taiwan)
  3. 3.Clinical experience of locally ablative RT in patients with oligometastasic NSCLC
    Sun Min Lim (Yonsei Cancer Center, Korea)

Satellite Symposium 14 (SL14)

Consideration treatment sequencing for ALK+ NSCLC
Date & Time Sep. 27 (Fri), 16:00-16:40 Venue Room E
Chair(s)
  • Jin Seok Ahn (Samsung Medical Center, Korea)
Presentation
Detail
  1. Real-world treatment patterns and effectiveness of subsequent treatments following 1L brigatinib from ALTA-1L
    Hee Kyung Ahn (Gachon University Gil Medical Center, Korea)

At this KSMO Annual Meeting, the “Asia-Pacific Research Networking Platform for Young Oncologists: It’s Time to Collaborate,” will be organized as a special session. This event will feature six insightful presentations from talented young oncologists representing Korea, Singapore, Thailand, Japan, and Australia. We will explore a range of topics on multinational studies in the Asia-Pacific region, including the challenges and opportunities in Asia-Pacific oncology; experiences in cross-border clinical research; overcoming clinical barriers such as ethical, cultural, and regulatory considerations; and how to leverage technology to overcome these limitations. We look forward to your participation and valuable contributions to foster collaboration and innovation in oncology research across the Asia-Pacific region.


이번 KSMO Annual Meeting에서 “Asia-Pacific Research Networking Platform for Young Oncologists: It’s Time to Collaborate”라는 특별 세션이 마련됩니다. 이 행사에서는 한국, 싱가포르, 태국, 일본, 호주를 대표하는 재능 있는 젊은 종양학자들의 여섯 가지 통찰력 있는 발표가 있을 예정입니다. 아시아-태평양 지역에서 다국적 연구를 위한 다양한 주제를 탐구할 것이며, 여기에는 아시아-태평양 종양학의 도전과 기회, 국경을 넘는 임상 연구의 경험, 윤리적, 문화적, 규제적 고려사항과 같은 임상적 장벽 극복, 그리고 이러한 한계를 극복하기 위해 기술을 활용 방안 등이 논의될 것입니다. 아시아-태평양 지역의 종양학 연구에서 KSMO가 이니셔티브를 가지고 협력과 혁신을 도모하는 기회가 될 것으로 생각됩니다. 

Scientific Symposium 1 will cover the present and future of breast cancer treatment. The first lecture will address the unique characteristics of breast cancer in pre-menopausal women and the treatment options based on these characteristics. The second lecture will feature a direct account from the developer on the journey of developing the targeted drug, Capivasertib. Finally, the third lecture will delve deeply into strategies for overcoming drug resistance in breast cancer.


이번 KSMO 2024에서 진행되는 Scientific Symposium 1 세션은 유방암 치료의 현재와 미래에 대한 내용을 담고 있다. 첫 번째 강연에서는 폐경 전 여성의 유방암의 고유한 특징과 이를 바탕으로 한 치료 옵션을 다룰 예정이다. 두 번째 강연에서는 타겟 항암제인 Capivasertib의 개발 여정을 개발자로부터 직접 들을 수 있다. 마지막으로, 세 번째 강연에서는 유방암에서의 약물 내성 극복 전략을 심도 있게 논의할 예정이다.

While targeting immune checkpoint molecules like PD-1/PD-L1 and CTLA-4 has significantly advanced cancer treatment, a substantial number of patients do not respond to these immune checkpoint inhibitors. This session will explore emerging immune checkpoint targets, including those expressed on T cells and B cells, as well as macrophage-focused strategies based on recent research. Emphasis will also be placed on identifying biomarkers to select patients who may benefit the most from these innovative therapies. Attendees will gain insights into the complex biology, latest research, and clinical status of these novel immune checkpoint targets, as well as their potential to enhance the efficacy of existing treatments.


PD-1/PD-L1와 CTLA-4와 같은 면역관문 분자를 표적으로 하는 치료법은 암 치료에 큰 진전을 가져왔지만, 여전히 많은 환자들이 이러한 면역관문 억제제에 반응하지 않는다. 이 세션에서는 최근 연구를 바탕으로 T 세포와 B 세포에서 발현되는 새로운 면역관문 표적과 대식세포 중심의 전략을 탐구하고, 이러한 혁신적인 치료에 반응하는 환자를 효과적으로 선별하기 위한 새로운 바이오마커에 대한 내용도 다룰 예정이다. 참가자들은 이러한 새로운 면역관문 표적의 생물학적 기전과 최신 연구 및 임상 상황, 그리고 기존 치료의 효과를 높일 수 있는 가능성에 대해 통찰해 볼 수 있을 것이다.

In this session titled "Oncology drug development: Translating biomarkers into breakthroughs," Professor Seung Bum Park from Seoul National University will introduce tumor treatment strategies that modulate the tumor microenvironment using the HMGB1 marker. Additionally, Professor Paul Workman from the Institute of Cancer Research, UK, will discuss the high potential of NXP800, a drug developed to activate GCN2 as a new therapeutic target, which has received FDA Fast Track and Orphan Drug designations for ovarian and bile duct cancers. Professor Seong-Wook Lee from Dankook University will also present his work on developing innovative RNA-based therapies targeting the telomerase reverse transcriptase enzyme for challenging cancers such as brain and liver cancer. These presentations are expected to greatly enhance understanding in the field of targeted oncology therapies by focusing on drug development targeting new markers.


“새로운 바이오마커를 통한 혁신적 종양 약물 개발"이라는 주제로 개최되는 이 세션에서는 현재 임상 1상이 진행되고 있는 새로운 바이오마커 기반 종양약물들의 초기 개발과정에 대해 소개할 예정이다. 서울대학교 박승범 교수가 HMGB1 마커를 활용하여 종양 미세환경을 조절하는 치료전략을 소개한다. 또한, 영국 ICR의 폴 워크맨 교수가 새로운 치료 표적으로서 GCN2를 활성화하는 전략으로 개발한 NXP800는  난소암 및 담도암에 대한 FDA의 패스트 트랙 및 희귀의약품 지정을 받으며 종양 치료제로서 높은 가능성을 보여주고 있다. 마지막으로 단국대학교 이성욱 교수는 뇌종양 및 간세포암과 같은 어려운 암을 대상으로 하는 텔로머라제 역전사 효소를 타깃으로 한 혁신적인 RNA 기반 치료법 개발에 대해 발표할 예정이다. 이러한 발표는 표적 종양 치료 분야의 새로운 표적을 공략하는 약물 개발 분야에 대한 이해를 넓히는 데 많은 도움이 될 것으로 기대한다.

This year’s genitourinary cancers session, entitled “The coming future of genitourinary cancer," will focus on drugs currently in the spotlight, or what will be established as standard treatment after clinical trials within a few years. For prostate cancer, updates on clinical trials on noble radioligand therapy as well as the recently introduced Lutetium-177-PSMA-617 (pluvicto) for urothelial carcinoma, an overview of the changing landscape of various treatments including antibody-drug conjugate, which has replaced the undisputed first-line platinum treatment for decades, will be discussed. For kidney cancer, research trends and treatment strategies in non-clear cell RCC, which are very urgent unmet medical needs, will be addressed. And finally, we have prepared lectures on adjuvant treatment strategies on various genitourinary cancers. We hope that this session will help you understand the latest hot topics and future research directions.


이번 비뇨기암 세션은 "the forthcoming future of genitourinary cancers"라는 제목으로, 현재 각광받는 약제들, 또는 수년 내에 임상시험을 마치고 표준치료로 자리를 잡게 될 것들을 주로 다룰 예정이다. 전립선암에서는 최근 도입된 Lutetium-177-PSMA-617 (pluvicto) 뿐 아니라 앞으로 나올 새로운 radioligand therapy와 임상시험 현황 소개, 요로상피암에서는 수십년간 부동의 1차치료로 자리잡은 platinum치료를 대체하게 된 antibody-drug conjugate를 비롯한 다양한 치료제와 치료방침의 변화 소개를 준비하였고, 신장암에서는 아직 불모지라 할 수 있는 non-clear cell RCC에서의 연구 트렌드와 치료전략 소개, 그리고 마지막으로 다양한 비뇨기암에서 adjuvant 치료전략에 대한 강의도 마련하였다. 이 세션을 통하여 현재의 핫 토픽과 앞으로의 연구방향을 이해하는 데 도움이 될 수 있을 것으로 기대한다.

Session description is currently being prepared. It will be available shortly.

This session highlights recent advances in the treatment of gastrointestinal (GI) cancers through targeted therapy and immunotherapy. This includes a focus on the use of KRAS inhibitors for gastrointestinal cancers and anti-HER2 therapy for these malignancies. Additionally, potential druggable targets beyond anti-VEGF for advanced hepatocellular carcinoma (HCC) will be explored. Finally, challenges and advances in immunotherapeutic approaches for pancreatic cancer will be presented. These presentations highlight ongoing research and clinical advances to improve outcomes for patients with gastrointestinal cancer.


이번 세션에서는 위장관암에서 표적치료와 면역치료에 대한 내용을 다루고자 한다. KRAS 억제제와 HER2 타깃 치료법에 대한 내용과 진행성 간세포암종에 대한 효과적인 치료약제 및 췌장암에 대한 면역치료에 대해 발표될 예정이다. 이번 세션을 통해 위장암관암에서 진행되는 연구들을 살펴보고 실제 진료에 적용될 가능성을 예상해보는 시간을 갖고자 한다.

Artificial intelligence technology is bringing significant transformations not only to the diagnosis and treatment of cancer but also to the development of anticancer drugs and biomarkers. Methodologies utilizing terabyte-scale data, such as whole-genome analysis, high-resolution pathological image analysis, and large-scale clinical and text information, are emerging. Revolutionary methods that enhance efficiency and shorten research periods by applying AI technology in the preclinical research stages, from the discovery of new targets to the initiation of clinical trials from early-stage compounds, are also being introduced. This session aims to present how AI technology, leveraging big data, is being practically applied in the fields of oncology drug and biomarker development.


인공지능 기술은 암의 진단과 치료 뿐 아니라, 항암신약 및 바이오마커 개발에도 큰 변혁을 가져오고 있다. 전장유전체 분석, 고해상도 병리이미지 분석, 그리고 대규모 임상정보 및 텍스트 정보 등 terabyte 단위의 데이터를 활용하는 방법론이 대두되고 있으며, 신규타겟 발굴 및 신약의 초기물질로부터 임상시험에 들어가기까지의 전임상연구 단계에서 인공지능 기술을 활용하여 효율성을 높히고 연구기간을 줄이는 획기적인 방법도 등장하고 있다. 본 세션에서는 이렇게 빅데이터를 활용한 인공지능 기술이 종양학 분야에서 신약 및 바이오마커 개발에 어떻게 실용적으로 적용되고 있는지 소개하고자 한다.

Recently, antibody-drug conjugates (ADCs) have emerged as an important therapeutic strategy across various cancer types, extending beyond major cancers (breast cancer, gastric cancer) to include other types such as gynecologic cancers. This session aims to review the new generation ADCs being researched which have achieved positive outcomes in various cancer types following the success of major ADC agents. In particular, the session will also focus on emerging tissue-agnostic ADC treatment strategies.


최근 antidody drug conjugate (ADC) 항암제는 유방암, 위암 등 주요 암종을 넘어서, 부인암을 포함한 다양한 암종에서 중요한 치료 전략으로 떠오르고 있다. 본 연제에서는 주요 ADC 항암제의 성공 이후에 각 암종에서 어떤 새로운 종류의 ADC항암제가 연구되고, 성공을 거두고 있는지를 확인하며, 특히 최근 대두되고 있는 tissue-agnostic ADC 치료 전략에 대해서 리뷰하고자 한다.

The last decade of medical oncology has shown unprecedented progress in cancer therapeutics which has led to a new paradigm of precision medicine. In parallel, the issue of toxicity should be more highlighted in the upcoming era. In this session, we will review and update several familiar as well as new major toxicities of treatment and further share practical tips for its management.


Medical oncology 역사에 있어 지난 10년은 표적 및 면역항암제를 필두로 암 치료제의 비약적인 발전이 이루어졌고 이를 근간으로 정밀의료의 패러다임을 맞이하게 되었다. 본 세션에서는 새로운 시대에 그 중요성이 보다 강조되는 독성 이슈와 관련하여, 임상가들이 반드시 숙지해야 할 주요 독성에 대한 최신 지견과 더불어 각 분야 전문가들의 실질적 관리 전략을 공유할 예정이다.

This session will introduce from the necessity and evidence of early integration of palliative care to practical application. First, we will address the necessity and optimal timing of integration of palliative care into the treatment plan, and then discuss the evidence for early integration of palliative care and the changes after the implementation of the “Act on Life-sustaining Treatment Determination” in Korea. Finally, we will focus on the two important methods of applying early integration of palliative care, prognostic disclosure and symptom monitoring. This session aims to present a comprehensive understanding and viable insights into early integration of palliative care.


이번 세션은 완화 치료의 조기 적용의 필요성 및 근거부터 실제적인 적용까지 소개하고자 한다. 먼저 완화의료를 치료계획에 통합해야 하는 필요성과 최적의 시점에 대해 다루고, 완화 치료의 조기 적용의 근거 및 우리나라 '연명치료결정에 관한 법률' 시행 후 완화 치료의 조기 적용의 변화에 대해 살펴볼 예정이다. 마지막으로, 완화 치료의 조기 적용에 있어서 중요한 두 가지 방법인 prognostic disclosure와 symptom monitoring을 중심으로 살펴볼 예정이다. 이번 세션은 완화 치료의 조기 적용에 대한 포괄적인 이해와 실행 가능한 통찰력을 제공하고자 한다.

This session, focused on the latest technologies and innovations in cancer treatment, will delve into the advancements and applications of artificial intelligence, robotic surgery, and digital therapeutics. Leading experts from each field will participate to share their latest research findings and clinical application cases, collaboratively exploring the future of cancer treatment.


암 치료의 최신 기술과 혁신을 주제로 한 이번 학술대회에서는 인공지능, 로봇 수술, 디지털 치료법의 발전과 적용에 대한 심도 있는 논의를 진행한다. 각 분야의 최고 전문가들이 참여하여 최신 연구 결과와 임상 적용 사례를 공유하고, 암 치료의 미래를 함께 모색하고자 한다.

Session description is currently being prepared. It will be available shortly.

The definition of rare cancer varies slightly from country to country and from year to year, but it is difficult to establish a standard treatment for cancer as large-scale phase 3 clinical trials pose a variety of challenges. However, with the recent breakthroughs in analytical techniques based on precision medicine, and in the development of therapeutic drugs, new changes have occurred in rare cancers. In this session, we will create a space where we can discuss the development of rare cancer drugs and the applications of these advances.


희귀암의 정의는 나라마다 시기마다 조금씩 다르지만, 대규모 3상 임상시험이 어렵기에 암치료의 표준요법을 확립하기가 어렵다. 하지만, 최근 정밀의료를 기반으로 한 분석기법과 치료제 약물개발의 획기적인 진보와 더불어 희귀암에서도 새로운 변화가 일어났다. 이번 세션에서는 그간의 희귀암의 약물개발부터 이러한 진보의 적용 등에 대해서 논의할 수 있는 장을 만들어볼 예정이다.

Session description is currently being prepared. It will be available shortly.

This session, a joint collaboration between the KSMO (Korean Society of Medical Oncology) and KSR (Korean Society of Radiology), will cover the latest research and applications of AI in oncology imaging while focusing on the current status and future perspectives of AI in various imaging modalities. Additionally, the session will include topics on predicting immunotherapy outcomes through advanced imaging techniques and provide an in-depth exploration of innovative advancements in oncology and radiology.


본 세션은 KSMO (대한종양내과학회)와 KSR (대한영상의학회)의 공동 세션으로, 종양 영상 분야에서 AI를 활용한 최신 연구 및 응용 사례등을 다룬다. 특히 각종 영상에서의 AI 활용 현황과 미래 전망, 그리고 진보하고 있는 영상기법등을 통한 면역치료 결과 예측 등의 주제를 포함한다. 이는 종양학 및 영상학 분야에서의 혁신적인 발전을 심도 있게 다룰 수 있는 기회가 될 것이다.

While immune check point inhibitors (ICIs) have established benefit in patinets with advanced disease, their role in perioperative management is evolving. This session will investigate the role of ICIs in the management of non-metastatic gastrointestinal cancers including gastric cancer, colon cancer and esophageal squamous cell carcinoma and lung cancer. Speakers will also review new treatment strategies and future practices for patients with these tumor types.


면역관문억제제(ICIs) 는 진행성 종양을 가진 환자들에게서 그 유효한 효과가 입증되었다.최근에는, 수술 전후 관리에서도 그 역할이 진화되고 있다. 본 세션에서는  위암, 대장암, 식도 편평 세포을 포함한 위장관암종 및 폐암 환자에서 비전이성  관리에서 (ICIs) 의 역할과, 향후 이러한 종양 유형을 가진 환자에서 새로운 치료 전략에 대해 알아볼 예정이다.

The digitalization of data stands as an indispensable prerequisite for fostering innovation in contemporary scientific and medical domains. The digitalization of pathology images has witnessed rapid advancement in recent years, seamlessly integrating into the landscape of hospital digital data analytics. Notably, it is anticipated to play a pivotal role as a cornerstone in the burgeoning realm of multi-data deep learning analyses. A fundamental objective of these digital pathologies lies in their utilization for patient diagnosis and treatment. This session will illuminate various endeavors undertaken across diverse facets of this journey. Specifically, we aim to elucidate the strides made in digital pathology through the lens of precision medicine, shedding light on the respective landscapes and initiatives of participating institutions.


데이터의 디지털화는 현대 과학 및 의료 분야의 혁신을 촉진하는 데 필수적인 전제 조건입니다. 병리 이미지의 디지털화는 최근 몇 년 동안 급속도로 발전하여 데이터 통합분석에 효율적으로 통합되고 있습니다. 특히, 급성장하고 있는 다중 데이터 딥러닝 분석 영역에서 필수적인 역할을 할 것으로 기대됩니다. 또한 디지털 병리의 근본적인 목적은 환자 진단과 치료에 활용되는 데 있습니다. 이 세션에서는 이 여정의 여러 측면에서 수행되는 다양한 노력을 조명하고자 합니다. 특히 정밀 의학의 관점에서 디지털 병리학의 진전을 설명하고 여러 기관의 각 환경과 이니셔티브를 조명하는 것을 목표로 합니다.

Session description is currently being prepared. It will be available shortly.

This session aims to highlight the latest research findings and clinical applications in the management of advanced gastrointestinal cancers through conversion surgery and systemic therapy. This session promises to offer valuable insights and foster meaningful discussions on innovative approaches in the treatment of advanced gastrointestinal cancers. We look forward to your active participation and engagement.


이번 세션은 진행성 위장관종양 및 간암의 conversion surgery와 전신항암요법에 대한 최신 연구 결과와 임상 적용에 대해 다룰 예정이다. 심도있는 강의 후 다양한 논의를 하고자 한다.

Session description is currently being prepared. It will be available shortly.

In this session, we aim to share the most recent knowledge on the integration of systemic treatment and radiation therapy (RT). First, Dr. Icro Meattini (University of Florence), a key member of the European Society for Radiotherapy and Oncology (ESTRO), will review the combination of antibody-drug conjugates or CDK4/6 inhibitors and RT in breast cancer. And Dr. Rodney Chen-En Hsieh (Chang Gung Memorial Hospital), who is actively working in the Taiwan Society for the Therapeutic Radiology and Oncology, will lecture on combined treatment including RT for HCC. Finally, Dr Sun Min Lim (Yonsei Cancer Center) will share clinical experience of locally ablative RT in patients with oligometastatic NSCLC from the medical oncologist’s perspective.


KSMO-KOSRO joint session에서는 다양한 암종에서 systemic treatment와 방사선치료의 병합치료에 대한 최신지견을 접하고자 한다. 유방암에서 향체-약물 접합체(antibody-drug conjugates)또는 CDK4/6 억제제와 방사선치료의 병합에 대하여 유럽방사선종양학회(ESTRO에서 활발하게 활동하고 있는 Icro Meattini (University of Florence) 선생님의 강의가 있으며, 간암에서 방사선치료가 포함된 병합 치료에 대하여 대만방사선종양학회에서 활발하게 활동 중인 Rodney Chen-En Hsieh (Chang Gung Memorial Hospital) 선생님의 강의가 있을 예정이다. 끝으로 연세암병원 임선민 교수님을 모시고 희소 전이 비소세포폐암에서 국소 방사선치료에 대한 임상 경험을 듣는 시간을 갖는다.

Regarding the optimal management for borderline resectable or locally advanced pancreatic cancer, a case-based multidisciplinary discussion will be held with experts in surgery (Prof. In Woong Han, Samsung Medical Center), radiation oncology (Prof. Eui Kyu Chie, Seoul National University Hospital), and medical oncology (Prof. Jin Won Kim, Seoul National University Bundang Hospital). This session will be conducted in Korean.


경계성 절제가능 췌장암과 국소진행 췌장암에서 최적의 치료법에 대해 외과 (삼성서울병원 한인웅 교수님), 방사선종양학과 (서울대병원 지의규 교수님), 종양내과 (분당서울대병원 김진원 교수님) 전문가들을 모시고 실제 증례를 바탕으로 한 다학제적 토의를 진행할 예정이다. 본 세션은 한국어로 진행된다.